Podcast appearances and mentions of rich stone

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

Join Nick and Rich Stone, founders of Nourish Lifestyle, as they share their incredible journey of rethinking how we eat, breathe, and move. In this episode, they reveal how they turned their lives around by growing their own food and reconnecting with nature. From their time in the French Alps to navigating the challenges of the pandemic, they offer actionable advice on living a more sustainable and holistic life. You'll learn:

Google Chrome is phasing out third parties cookies by the end of the year. All the other browsers are already blocking them, Safari, Firefox etc...We talk about what online marketing looks like after 3rd party cookies are gone. About Rich StoneRich is a B2B tech intent data SaaS sales VP with 16 years of experience across a number of sales and leadership functions within TechTarget. Currently leading a team of Enterprise Sellers in North America in fostering mutually beneficial partnerships with our largest and most strategic customers in North America. Working diligently to ensure success across our customers' B2B technology marketing and sales goals / KPIs. Providing solutions that make a real business impact for our customers across our full suite of TechTarget's offerings including BrightTALK, Enterprise Strategy Group, Data Science Central and Xtelligent Healthcare Media.EPISODE LINKSTechTarget PLEASE follow and tell a friend about the MARKETING Podcast.CONNECT WITH USClaim Your Marketing EdgeA weekly email written by your host Brandon White that gives you an edge in your marketing.Over 17,200 subscribers and counting--> https://edge.ck.page/bea5b3fda6SHOW INFORMATIONMARKETING Podcast Websitehttps://PodcastOnMarketing.comOTHER GREAT PODCASTS YOU'LL LOVE FROM THE BEST PODCASTS NETWORKBUSINESS PLAN PodcastEverything you need to know on how to write a business plan in 11 slides.https://businessplan.buzzsprout.comThe Brandon White ShowRanked in the top of the charts, 475 episodes, your get conversations worth listening. About business, technology, peak performance, health, sports, exploration, music, art, science, philosophy, love, and power. https://MyEdgePodacst.comPRODUCTIVITYProductivity tips in under 5 minuteshttps://podcasts.apple.com/us/podcast/productivity/id1694396715

On this week's show: The impact of war on science in Ukraine, and a conversation with Anthony Fauci as he prepares to step down Some scientists in Ukraine have been risking their lives to protect scientific facilities, collections, and instruments amid the war. Contributing Correspondent Richard Stone traveled to Kharkiv and Chornobyl earlier this year to meet researchers living and working through the conflict. He spoke with host Sarah Crespi to share some of their stories. Then we have a conversation with Anthony Fauci, who will be stepping down from his government roles this month after more than 50 years in public service. He shares his thoughts on the ongoing challenges of communicating about science and public health, combating misinformation, and his goals for the future with Science Editor-and-Chief Holden Thorp. Take our audience survey at: https://www.science.org/podcasts This week's episode was produced with help from Podigy. [Image: Rich Stone; Music: Jeffrey Cook] [alt: photo of rubble damaged during war in Ukraine with building spire in background]  Authors: Sarah Crespi; Rich Stone; Kevin McLean; Holden Thorp Episode page: https://www.science.org/doi/10.1126/science.adg1712 About the Science Podcast: https://www.science.org/content/page/about-science-podcastSee omnystudio.com/listener for privacy information.

On this week's show: The impact of war on science in Ukraine, and a conversation with Anthony Fauci as he prepares to step down Some scientists in Ukraine have been risking their lives to protect scientific facilities, collections, and instruments amid the war. Contributing Correspondent Richard Stone traveled to Kharkiv and Chornobyl earlier this year to meet researchers living and working through the conflict. He spoke with host Sarah Crespi to share some of their stories. Then we have a conversation with Anthony Fauci, who will be stepping down from his government roles this month after more than 50 years in public service. He shares his thoughts on the ongoing challenges of communicating about science and public health, combating misinformation, and his goals for the future with Science Editor-and-Chief Holden Thorp. Take our audience survey at: https://www.science.org/podcasts This week's episode was produced with help from Podigy. [Image: Rich Stone; Music: Jeffrey Cook] [alt: photo of rubble damaged during war in Ukraine with building spire in background]  Authors: Sarah Crespi; Rich Stone; Kevin McLean; Holden Thorp Episode page: https://www.science.org/doi/10.1126/science.adg1712 About the Science Podcast: https://www.science.org/content/page/about-science-podcastSee omnystudio.com/listener for privacy information.

In Part Two of this Oncology, Etc. episode, hosts Patrick Loehrer and David Johnson continue their chat with hematologist-oncologist Dr. David Steensma. They explore his views of key opinion leaders and a lifelong passion – collecting rare stamps, including medical stamps. If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org.   TRANSCRIPT Pat Loehrer: Hi, I'm Pat Loehrer, Director of Global Oncology and Health Equity at Indiana University. I'm here with Dave Johnson, a Medical Oncologist from The University of Texas, Southwestern in Dallas, Texas. Welcome to the second half of our Oncology, Etc. conversation with Dr. David Steensma. He's a highly accomplished physician and scientist in the field of Hematology/Oncology. In the first part of this episode, Dr. Steensma told us about his Dutch immigrant roots, and how a single college biology course changed his career interests from astronomy into medicine. Today, we'll explore his views on Key Opinion Leaders and another passion of his, and an interest of ours - collecting rare stamps, including medical stamps. Dave Johnson: So, David, in addition to your scientific writing, you've been a prolific writer in many other sort of viewpoints and opinion pieces. There's a lot to choose from, but I know you've been interviewed in the past about your column called ‘The Raven', which I won't ask you about, as an Edgar Allen Poe fan. You also wrote a wonderful piece called, ‘Key Opinion Leaders', which I thought might be quite interesting to ask you about, now that you might be calling upon KOLs. Do you want to tell us a little about that? Dr. David Steensma: Yeah, that's not my favorite term. Thought Leaders is another kind of silly term, but we know what we mean when people are talking about it. Yeah, I've had a chance to write on a lot of different things over the years, and that's been great fun. And when I first heard that term, I couldn't figure out what it meant, KOL. And then, a pharmaceutical representative actually accidentally left a list of KOLs in my office and I realized that not only are KOLs cultivated very carefully, those relationships, but there's a hierarchy of KOLs. They were people who influenced the local formulary and local practice at the institution, there were those who had a regional impact, and then there were those who were on the NCCN guideline committees, and had, you know, much broader impact that they really wanted to make sure to influence the heart and minds of-- in my interactions now, this opinion piece was a sort of tongue-in-cheek about Key Opinion Leaders and Thought Leaders. And with Thought Leaders, I was reminded of Sherlock Holmes's brother Mycroft Holmes, who, by Conan Doyle's fiction, was a brilliant man, but unwilling to stir his ample backside from his Chair in the Diogenes Club to actually get out there, and do some real work, and solve mysteries. And so, it fell to his slightly less brilliant brother, Sherlock, to become the consulting detective. So, that was fun. Now, we're sort of on the receiving end of wisdom from people who are experts in the area. And it's very important what doctors think, and in different geographies about how they think their patients will be potentially treated in a year or two, five years down the road, what the issues they have with current approaches are, where they see opportunity for some of our new compounds, for some of those of other companies, and it's different in Europe versus the US versus Australia. And so, there's a lot that we gain from advisory boards. There's an arc to an advisory board. You don't want to convene an advisory board when there's no data, because then, everybody is just speculating. You don't want to do it too late after something is already on the doorstep of FDA approval because then not anything can be changed at that point. So, you know, doing it at an in-between point where there's some initial data, but where we can really be guided by academic, clinical, and other experts, is really helpful. Pat Loehrer: I'd encourage people to pull this article out. It is really, really good. 2015, I think it came out there. The end of it, I also love it. You're talking about Kanti Rai who came up with the Rai classification and he was at this Meet the Expert session at the ASH meeting, and he said at the meeting, and this is your quote from it, and I love it, he said, “I don't like the name of this session because no one's an expert in chronic lymphocytic leukemia. I've been studying this disease for decades, and still too many of my patients die. If I was truly an expert, the disease would've been cured by now." I just love it, but it's a great read. Dave Johnson: Let me ask you, very seriously, if a younger colleague were to come to you, David, what advice would you give him or her about being invited to be on an advisory board? We'll skip the term KOL or Thought Leader. What advice would you give him or her, and what should they look for, and how should they prepare for that activity should you think they should do it? Dr. David Steensma: Well, I think getting back to imposter syndrome, people should feel, if they're invited to be in such a meeting, that they're there for a reason because their opinion does matter. And sometimes, younger physicians are reluctant to speak up in this setting, especially when there maybe leaders in the field there that have been doing it for decades, and may have very strong opinions. So, not being afraid to share their perspective and realizing that they're invited for a reason. On the other hand, I found it very helpful when I was a young faculty member and, on these panels, to listen to how colleagues were assessing data, and the recommendations they were making, and their perspective. And I learned a lot from some of those advisory boards earlier on. Many of the people who are the senior leaders in leukemia and MDS, you know, Rich Stone, Peter Greenberg, you know, John Bennett, in MDS, Marty Tallman, Hagop Kantarjian, Clara Bloomfield, just people who had decades of experience. And in part, I think it's some of my comments at advisory boards that helped get me my job at Dana-Farber, because I'd been in a number of meetings with Rich Stone, and he apparently liked some of the things I'd said about approaching patients. And so, you know, when a faculty position came open, he invited me out to come visit. And so, they can have benefits that you don't anticipate. Dave Johnson: Yeah, I would definitely agree with that. And there's pros and cons to being involved in those activities, but there are an awful lot of good that comes from it. And I think you've just touched on some of those. I'm going to shift gears a little bit because Pat has been waiting anxiously to hear all about your stamps. So, out of the many, many things that you've done and written about, I would say you've got close to 100 publications on medical stamps. It's an extraordinary productivity, David. So, tell us a little about your interest in medical stamps. How did you get involved in this, and where do you find time to write about them, and how do you decide which ones you're going to write about? Dr. David Steensma: Yeah. Bob Kyle, is really the driver on that, and we continue to do these together. Bob turned 94 this year, and he continues to be intellectually engaged. He's fun to talk to, if it weren't for COVID, he'd still be traveling and coming into the office, you know, which he was doing until just a few years ago. So, I met Bob as an intern when I was at Mayo. Somebody said, "Oh, you should meet this guy, he's really fun to talk to." And we just hit it off. And when I was a boy, my grandfather and my great-grandfather had collected stamps. And my grandfather really got me interested in it, partly given our family history, those of The Netherlands and former colonies, but also just more generally. And then as often happens, I got to be a teenager and other things took over in terms of interest, and there was less time, so, I had fallen away from it a bit. But somehow in this conversation, Bob had mentioned this, and that they were looking for someone younger who had this kind of background, to help with this series that has been running. Initially, it was running in JAMA with a guy named John Mirt, beginning around 1960, and then about a decade later, moved to the Mayo Clinic proceedings when they published six stamp vignettes on medical science per year, and Bob has done over 500 of these going back decades. And so, I got involved in that, and writing about-- thus far, it's mostly focused on individuals, but I have done a few also about more general trends in Philately. I will say that there are fewer of us, certainly those under 50, who are involved in the hobby. There's so much other distractions, but I still find it interesting and fun. And I've learned a lot, putting those vignettes together. Pat Loehrer: I started collecting stamps when I was young, I still have my Scott's album down. And now it's not stored, in properly, but I remember US Number One, I could have bought for $35, but I was only like 10 years old, and that was, you know, like $500 to me. So, I still regret that. Are you collecting stamps yourself now, still that you've resumed the collection part of it? Dr. David Steensma: Yeah. I would say, only a little bit. So, my Netherlands and Colonies collection is now actually complete, except there's one elusive. There's always one, right? Can't find this thing, even at auctions and such. And I also collected coins as a kid, and you know, still have some involvement in that. It's hard to find the time because I do do so many other things, and my wife and I have children, they're now college and PhD age, so I do woodworking, I have a telescope, so I never lost the love of astronomy. It seems like there's always other things to do. But I still have my collection over there on the shelf. Pat Loehrer: Did you inherit it from your grandfather too? Dr. David Steensma: Some of it I did. Yep. The core of it, I inherited from my grandfather and my great-grandfather. And then once I paid off my substantial medical school debt to the University of Chicago with the help of, in part, from advisory boards, but also mostly from moonlighting in emergency rooms around rural Minnesota-- during fellowship, I was like a full-time ER doc who happened to be doing a Hem/Onc Fellowship on the side, and finally got it paid off and then I could start on filling in some of the gaps. Pat Loehrer: Before we change this thing, what is your most cherished stamp that you own? Dr. David Steensma: Oh, my most cherished stamp is not a Dutch one. It is a set of national park stamps from 1934, authorized by James Farley, who was the Postmaster General at that point. 10 stamps, different colors about, you know, Zion and Acadia-- and it was my grandfather's favorite, and he was a big fan of the national parks, took two big trips there back in the '50s out West. And so, at his funeral, I put together a little display of those hanging with the photographs of other things from his life. I have that display, it's very meaningful to me - it's a connection with him. He was certainly very influential in my life. I never imagined I'd be working for a Basel-based pharmaceutical company, like he did for his whole career. Never thought that that would happen, but life has some unexpected twists. He worked for Roche in Nutley, New Jersey for much of his career as a research chemist. And ironically, when my grandmother was diagnosed in the 1990s, pancreatic cancer, and she saw the oncologist and was offered a 5-FU infusion after surgical, he said, "5-FU. I worked on that in 1959, 1960, that's still the best that we have to offer?" He was shocked by that. I was a fellow at the time. I said, "We need better drugs." Dave Johnson: For sure. So, do you have a favorite medical stamp, David? Dr. David Steensma: A favorite medical stamp? Gosh, that one's I think a little bit harder. I certainly have medical stamps that have piqued my interest. One of the sort of most moving is one of the US stamps that came out in the 1950s that has the Sir Luke Fildes' ‘The Doctor', on it. You know, with this concerned physician at the bedside of a young boy, and I actually wrote a vignette about the history and background there, and I think that connection with patients at the end of the day when we don't have good drugs, that connection with patients is still so meaningful, isn't it? As you guys really know. So, and as many of our listeners know, and so much of what medicine remains despite the molecular glue degraders and CAR T and gene therapy, is still that human connection, and being there for our patients. And so, I would say that that is probably one of the most meaningful. There's some real quirky ones, too. Austria's come out with some stamps in the last few years; one made of toilet paper, when the toilet paper shortage was happening, another, made of the mask material and the shape of the mask to remind people to mask up. You know, there's been a lot of creativity. And the Dutch are very good about design. They come up with just some brilliant innovations in postage stamps. Dave Johnson: I mean, stamps are really quite artful, by the way, the Fildes painting hangs on the wall of my office. You can't see it, but it's on the wall. And then behind me, you can perhaps see a couple of framed stamps that are some of my favorites. One was a gift to me from a former Group of Chief Residents, of an Osler stamp that Canada put out, and the other is one I received actually as a gift, as part of an award. It's the first cancer stamp that was produced in the United States. So, I love them both. They're quite nice. The Fildes stamp is actually my favorite of all, so I think that's a great stamp. Pat Loehrer: I have actually looked behind me. I've got a stamp collection on the frame that was given to me too that I love. It's stamps of medicine. There was one, a Dag Hammarskjöld stamp, that was famous because they printed it upside down when they put the color in, and I think it created a huge controversy from-- you know this better than I do because they decided then just to overprint them. Instead of making a few sheets that were incredibly valuable, they ended up printing out thousands of these things, which I have one now. It's only worth 7 cents, but at the time, it seemed really cool to have a misprinted stamp in your collection. Dr. David Steensma: Dag Hammarskjöld, there's an interesting connection with what I was talking about a little bit earlier with St. Elizabeth's Hospital. So, this relatively small teaching hospital had, at one point, a very strong hematology research program led by a guy named Fred Stallman. And in 1974, Fred Stallman, who was coming back from ISH, International Society Hematology, which was in Tel Aviv that year, and his plane exploded somewhere over the Aegean Sea, ultimately thought to be related to the PLO, and so he died. There was a big painting on the wall, in the hospital of him. And Dag Hammarskjöld also, at the peak of his career, you know, as the UN Secretary-General, was killed in a plane crash. But the interesting thing about Fred Stallman is, here, you have somebody who was so important in hematology. None of the fellows had any idea who he was or their connection to hematology. You know, it shows how fleeting fame is, unless you're an Einstein or Babe Ruth level. So, that was a good thing to keep in mind as well. Pat Loehrer: We could talk for another hour or two on this. Dave, we really appreciate it. But unfortunately, this is all the time we have for today. And I really want to thank you for joining us, Dave. This has been a wonderful conversation. I also want to thank all our listeners for tuning in to Oncology, Etc. This is an ASCO Education broadcast where we will talk about anything and everything, as you can imagine. If you have an idea for a topic or a guest you'd like to see on the show, just email us at: education@asco.org. Thanks, again. And, Dave, I've got a quiz for you here. Do you know why pirates don't take a shower before they walk off the plank? Dr. David Steensma: I do not. Dave Johnson: I have no idea. Pat Loehrer: It's because they wash up on shore. Dave Johnson: Oh boy.   Thank you for listening to the ASCO Education podcast. To stay up-to-date with the latest episodes, please click, "Subscribe." Let us know what you think by leaving a review. For more information, visit the Comprehensive Education Center at: education.asco.org.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.

On this episode I'm joined by Rich Stone, founder and head roaster at Memoirs Coffee Roasters. We sit to talk about coffee processing, fair compensation, the Florida scene, his background in coffee, and the Memoirs story. During the episode Rich was having a termico processed Costa Rican single-origin and I was having Salma Bermudez by Manhattan Coffee. Episode Links: https://www.memoirscoffee.com/ https://manhattancoffeeroasters.com/ https://handstotheforsaken.bandcamp.com/album/fight-to-reclaim https://www.beansandbreakdowns.com/ --- Send in a voice message: https://anchor.fm/beansandbreakdowns/message

On this week's show: Plans to push a modern space probe beyond the edge of the Solar System, crustaceans that pollinate seaweed, and the latest in our series of author interviews on food, science, and nutrition After visiting the outer planets in the 1980s, the twin Voyager spacecraft have sent back tantalizing clues about the edge of our Solar System and what lies beyond. Though they may have reached the edge of the Solar System or even passed it, the craft lack the instruments to tell us much about the interstellar medium—the space between the stars. Intern Khafia Choudhary talks with Contributing Correspondent Richard Stone about plans to send a modern space probe outside the Solar System and what could be learned from such a mission. Next up on the show, Myriam Valero, a population geneticist at the evolutionary biology and ecology of algae research department at Sorbonne University, talks with host Sarah Crespi about how a little crustacean might help fertilize a species of algae. If the seaweed in the study does use a marine pollinator, it suggests there may have been a much earlier evolutionary start for pollination partnerships. Finally, we have the next in our series on books exploring the science of food and agriculture. This month, host Angela Saini talks with biochemist T. Colin Campbell about his book The Future of Nutrition: An Insider's Look at the Science, Why We Keep Getting It Wrong, and How to Start Getting It Right.   This week's episode was produced with help from Podigy.   [Image: Johns Hopkins APL/Mike Yakovlev; Music: Jeffrey Cook]   [alt: illustration of an interstellar probe crossing the boundary of the heliosphere with podcast symbol overlay]   Authors: Sarah Crespi; Rich Stone; Angela Saini; Khafia Choudhary   ++ LINKS FOR MP3 META   Episode page: https://www.science.org/doi/10.1126/science.ade1292     About the Science Podcast: https://www.science.org/content/page/about-science-podcastSee omnystudio.com/listener for privacy information.

On this week's show: Plans to push a modern space probe beyond the edge of the Solar System, crustaceans that pollinate seaweed, and the latest in our series of author interviews on food, science, and nutrition After visiting the outer planets in the 1980s, the twin Voyager spacecraft have sent back tantalizing clues about the edge of our Solar System and what lies beyond. Though they may have reached the edge of the Solar System or even passed it, the craft lack the instruments to tell us much about the interstellar medium—the space between the stars. Intern Khafia Choudhary talks with Contributing Correspondent Richard Stone about plans to send a modern space probe outside the Solar System and what could be learned from such a mission. Next up on the show, Myriam Valero, a population geneticist at the evolutionary biology and ecology of algae research department at Sorbonne University, talks with host Sarah Crespi about how a little crustacean might help fertilize a species of algae. If the seaweed in the study does use a marine pollinator, it suggests there may have been a much earlier evolutionary start for pollination partnerships. Finally, we have the next in our series on books exploring the science of food and agriculture. This month, host Angela Saini talks with biochemist T. Colin Campbell about his book The Future of Nutrition: An Insider's Look at the Science, Why We Keep Getting It Wrong, and How to Start Getting It Right.   This week's episode was produced with help from Podigy.   [Image: Johns Hopkins APL/Mike Yakovlev; Music: Jeffrey Cook]   [alt: illustration of an interstellar probe crossing the boundary of the heliosphere with podcast symbol overlay]   Authors: Sarah Crespi; Rich Stone; Angela Saini; Khafia Choudhary   ++ LINKS FOR MP3 META   Episode page: https://www.science.org/doi/10.1126/science.ade1292     About the Science Podcast: https://www.science.org/content/page/about-science-podcastSee omnystudio.com/listener for privacy information.

Rich Stone, Vice President of Sales West of TechTarget reveals why intent data has become a dirty word for sales and marketing teams despite all the good it brings to an organization. Host Jennifer Gutman of Oktopost welcomes Rich as they explore some good old-fashioned sales and marketing alignment through intent data. Rich hints that sales and marketing can generate pipeline and revenue faster when exploring someone's intent to buy through directly observing the data together. He reveals why social selling is his secret sauce when it comes to outperforming his peers and gets “radically transparent” about why the most talented marketers have been in sales. Rich even shares a few tactics on how he's been able to motivate his teams over the years, hint: long vs. short hair!

Rich was a pleasure to speak with! In this episode, we discuss his journey launching the coffee roastery he built from the ground up just a few weeks ago.  We go into some detail on his 2kg Mill City coffee roaster and his Ikawa Pro sample roaster.  We also dive into his career in coffee and his time working for a larger coffee roastery, "Pete's Coffee". I truly hope you enjoy this episode. Memoirs: https://www.memoirscoffee.comIG. https://instagram.com/memoirscoffee?utm_medium=copy_linkSupport the show (https://www.patreon.com/robpirie?fan_landing=true)

Rich Stone, former international news editor at Science and current senior science editor at the Howard Hughes Medical Institute's Tangled Bank Studios, joins host Sarah Crespi to talk about concerning levels of fission reactions deep in an inaccessible area of the site of the 1986 Chernobyl nuclear disaster. Though nothing is likely to come of it anytime soon, scientists must decide what—if anything—they should do tamp down reactions in this hard-to-reach place. Also on this week's show, Shlomi Kotler, an assistant professor in the department of applied physics at the Hebrew University of Jerusalem, joins Sarah to discuss the quantum entanglement of macroscopic objects. This hallmark of quantum physics has been confined—up until now—to microscopic items like atoms, ions, and photons. But what does it mean that two drums, each the width of a human hair, can be entangled? Read a related insight. This week's episode was produced with help from Podigy. Listen to previous podcasts. About the Science Podcast Download a transcript (PDF). [Image: Caption: New Safe Confinement structure built over Chernobyl ruins; Credit: URBEX Hungary/Flickr; Music: Jeffrey Cook] Authors: Rich Stone; Sarah Crespi See omnystudio.com/listener for privacy information.

Rich Stone, former international news editor at Science and current senior science editor at the Howard Hughes Medical Institute's Tangled Bank Studios, joins host Sarah Crespi to talk about concerning levels of fission reactions deep in an inaccessible area of the site of the 1986 Chernobyl nuclear disaster. Though nothing is likely to come of it anytime soon, scientists must decide what—if anything—they should do tamp down reactions in this hard-to-reach place. Also on this week's show, Shlomi Kotler, an assistant professor in the department of applied physics at the Hebrew University of Jerusalem, joins Sarah to discuss the quantum entanglement of macroscopic objects. This hallmark of quantum physics has been confined—up until now—to microscopic items like atoms, ions, and photons. But what does it mean that two drums, each the width of a human hair, can be entangled? Read a related insight. This week's episode was produced with help from Podigy. Listen to previous podcasts. About the Science Podcast Download a transcript (PDF). [Image: Caption: New Safe Confinement structure built over Chernobyl ruins; Credit: URBEX Hungary/Flickr; Music: Jeffrey Cook] Authors: Rich Stone; Sarah Crespi See omnystudio.com/listener for privacy information.

Rich Stone, former international news editor at Science and current senior science editor at the Howard Hughes Medical Institute’s Tangled Bank Studios, joins host Sarah Crespi to talk about concerning levels of fission reactions deep in an inaccessible area of the site of the 1986 Chernobyl nuclear disaster. Though nothing is likely to come of it anytime soon, scientists must decide what—if anything—they should do tamp down reactions in this hard-to-reach place. Also on this week’s show, Shlomi Kotler, an assistant professor in the department of applied physics at the Hebrew University of Jerusalem, joins Sarah to discuss the quantum entanglement of macroscopic objects. This hallmark of quantum physics has been confined—up until now—to microscopic items like atoms, ions, and photons. But what does it mean that two drums, each the width of a human hair, can be entangled? Read a related insight. This week’s episode was produced with help from Podigy. Listen to previous podcasts. About the Science Podcast Download a transcript (PDF).

Rich Stone is back with some absolute FIRE on this week's podcast.  You may remember Rich as our 1st ever guest on episode 1, where he spoke about his mantra of "attitude and effort".  This is an ultimate guide for how to have a successful career.  We talk about the fundamentals of working hard and having the right attitude and more thoughts like playing the long game, which is something most millennials miss. The one thing that really stands out about Rich is his confidence.  His advice?  "The work comes before the belief."  Put another way, confidence comes from doing the work time and time again.  You don't want to miss this one. ***FYI I am being told there's a gap between minute 2 of the intro and minute 5 where I kick off with Rich.  Please fast forward and sorry for the inconvenience!*** Connect with me at @TommyTahoe on Twitter, Instagram, and YouTube Connect with Rich at @Rstone57 on Twitter and Instagram  

Rich Stone is back with some absolute FIRE on this week's podcast.  You may remember Rich as our 1st ever guest on episode 1, where he spoke about his mantra of "attitude and effort".  This is an ultimate guide for how to have a successful career.  We talk about the fundamentals of working hard and having the right attitude and more thoughts like playing the long game, which is something most millennials miss. The one thing that really stands out about Rich is his confidence.  His advice?  "The work comes before the belief."  Put another way, confidence comes from doing the work time and time again.  You don't want to miss this one. ***FYI I am being told there's a gap between minute 2 of the intro and minute 5 where I kick off with Rich.  Please fast forward and sorry for the inconvenience!*** Connect with me at @TommyTahoe on Twitter, Instagram, and YouTube Connect with Rich at @Rstone57 on Twitter and Instagram  

in today podcast Andy is joined by co-host Rich Stone and special guest Lee James Peake from the Untiltled Film Podcast to talk about Wrestlemania 6

In today's show Andy is joined by Rich Stone and Lee James Peake and they guys go into extra time as they talk about possibly the greatest Summerslam ever!!

Attitude and effort. These are two of the only things that we can control and are key factors to every single successful person in the world. Whether it's through sports, sales, or life, Rich Stone has focused on these two areas - and it's served him well. Rich brings with him 10+ years of technology sales and was named Sales Rep of the Year at his company in 2014. He has 15+ years in competitive athletics and played football at St. Anselm College. He has contributed blogs and podcasts to Salesforce Quotable and is seen as a thought leader in social selling. Currently, he is a husband, father of two, and VP Sales at TechTarget. All of those accomplishments - and any on the horizon - are due to the attitude and effort he puts in to his day-to-day tasks. In this episode, we talk about how sports and competition as a kid help you later in life, his mantra of “Attitude is everything” and tactical sales advice that anyone can apply today. This is the first episode of the Millennial Momentum Podcast (formerly TR Talk). We hadn't' quite figured out the audio at this point, so please bear with us. Hope you enjoy. "Attitude is everything" - Rich Stone Listen Here: iTunes Google Play Stitcher Sign up for the weekly Millennial Momentum Newsletter. No BS, All hustle

Attitude and effort. These are two of the only things that we can control and are key factors to every single successful person in the world. Whether it’s through sports, sales, or life, Rich Stone has focused on these two areas - and it’s served him well. Rich brings with him 10+ years of technology sales and was named Sales Rep of the Year at his company in 2014. He has 15+ years in competitive athletics and played football at St. Anselm College. He has contributed blogs and podcasts to Salesforce Quotable and is seen as a thought leader in social selling. Currently, he is a husband, father of two, and VP Sales at TechTarget. All of those accomplishments - and any on the horizon - are due to the attitude and effort he puts in to his day-to-day tasks. In this episode, we talk about how sports and competition as a kid help you later in life, his mantra of “Attitude is everything” and tactical sales advice that anyone can apply today. This is the first episode of the Millennial Momentum Podcast (formerly TR Talk). We hadn't’ quite figured out the audio at this point, so please bear with us. Hope you enjoy. "Attitude is everything" - Rich Stone Listen Here: iTunes Google Play Stitcher Sign up for the weekly Millennial Momentum Newsletter. No BS, All hustle

Hello Listeners, Rhys, Ross, Carina and Clay are joined by True Achievements Rich Stone to go over the hottest topics on the subreddit, discuss which games should go in the bin and the Achievements challenge draws to a close... But who won?

This week we hear stories on involving more AIs in negotiations, tiny algae that might be responsible for killing some (not all) dinosaurs, and a chemical intended to make farm fish grow faster that may be also be causing one area's crocodile population to skew male—with Online News Editor David Grimm.   Sarah Crespi talks to Rich Stone about being on the scene for a joint U.S.-China mission to remove bomb-grade fuel from a nuclear reactor in Ghana.   Listen to previous podcasts.    [Image:Chad Sparkes; Music: Jeffrey Cook]

This week we hear stories on involving more AIs in negotiations, tiny algae that might be responsible for killing some (not all) dinosaurs, and a chemical intended to make farm fish grow faster that may be also be causing one area’s crocodile population to skew male—with Online News Editor David Grimm.   Sarah Crespi talks to Rich Stone about being on the scene for a joint U.S.-China mission to remove bomb-grade fuel from a nuclear reactor in Ghana.   Listen to previous podcasts.    [Image:Chad Sparkes; Music: Jeffrey Cook]

"Attitude and effort are the two things that we can control." Rich Stone is the VP Sales at TechTarget. In this episode, we discuss Rich's perspective on how millennials can win through mental preparation, social selling, and more. Sign up for the weekly Millennial Momentum Newsletter. No BS, All hustle

If you missed it yesterday, my friend Ryan Warner and I released our first podcast. I’ve been listening to podcasts more and more in the last year. Regardless if your interest is in business, sports, history or otherwise, there is no shortage of tremendous content. That said, we thought there was a hole in the market for a podcast run by Millennials, for Millennials that focused on how people of our age can break out of the negative stigma. On TR Talk, we interview leaders in their respective fields to learn how millennials can make an impact in today’s workforce. The goal here is to gain some practical knowledge from people that we admire and can add a lot of value to our audience. For episode 1, we interviewed Rich Stone, VP Sales at TechTarget, titled “Attitude is Everything”. Rich was a great guest and gave us his perspective on how millennials can win through mental preparation, social selling and more. We have some great guests lined up and are fired up to bring this to everyone. We’re looking to post every other week. Sign up for the weekly Millennial Momentum Newsletter. No BS, All hustle

Rich Stone: TrueAchievement himself from www.trueachievements.com joins us for an in-depth chat about TA and what makes it tick; Damien shovels some wares; and we find out why cows don't like daylight savings. Show notes are always available on the Zed to Zed website We are on iTunes, Stitcher and Google Play! Please give us a rating or review, it will really help us and is a free, easy way to support the show! Contact us! Twitter: @zedtozed Facebook: Zed to Zed Podcast Email contact@zedtozed.com PM any of the hosts on TrueAchievements Comment on the dedicated podcast post on zzUrbanSpaceman's blog Join the Zed to Zed Forums Also check out the Zed to Zed Podcast Leaderboard on TrueAchievements. Hosts: Brandon Fream aka "Freamwhole" - TrueAchievements / Xbox / Twitter Tarragon Allen aka "zzUrbanSpaceman" - TrueAchievements / Xbox / Twitter Jo aka "angelsk" - TrueAchievements / Xbox / Twitter Damien aka "Spazpol" - TrueAchievements / Xbox / Twitter Guest: Rich Stone aka “TrueAchievement” - TrueAchievements / Xbox / Twitter 0:00:00 - Intro 0:12:13 - Recap 0:24:46 - Listener Feedback 0:32:55 - News 0:57:11 - Talking Zeds with Rich Stone of TrueAchievements.com 2:27:32 - Shovelware Cemetery Dungeon Of The Endless - Xbox Live / TrueAchievements Action News Heroes -  Xbox Live / TrueAchievements Inside - Xbox Live / TrueAchievements 2:46:06 - Backwards Compatibility, Game Delays, Zombie News Referenced during the show: INSIDE explanation video (spoilers) Fream defeats a wall Mega-Man Master Chief etched in every X1-S Shadow Kisuragi blog about Windows Phone game compatibility Using a paper dummy with a fan for Xbox Fitness “Peak Performance” Shinji Kagawa & Hiroshi Kiyotake VS 55 Kids Dungeon of the Endless Action News Heroes Inside All audio production and podcast backend support provided by Tarragon Allen. Songs and sounds that have been used in the show: "Jive Bot", “Tally Screen” (x2), “Dalmation Station (It Gets Better Mix)” by Jake Kaufman from the games Mighty Switch Force! 1 and 2, developed and published by WayForward Technologies "Game Cool Dubstep Mode Logo" by Sparximer Epic Voice Announcements by RJBANKSWA crickets by rucisko Solo Zombie 1 by Slave2theLight Murder by Shovel by JenniferSJF Shovel digging into dry dirt (SFX) by MorneDelport FP_Burial_In_Wooden_Coffin by cmusounddesign   Glossary of Xbox Gamerscore and achievement jargon and terms  

Ross Clay and Rhys talk Red Dead redemption, The ID at Xbox making huge amounts for developers and Video Game Movies. Rich Stone from trueachivments.com joins us for a Chat about developing a website and app on the Xbox platform.

011 - Gummy Gummy Gummy Gummy Some unique listener feedback, Fallout 4 mod support, Fream's contest, major GS milestones. BONUS Life Is Strange Spoilercast after the main show. Show notes are available on http://www.zedtozed.com/ Please give us a rating or review in your favourite podcast application, it will really help us spread the word and make the show a success! Contact us on Twitter @zedtozed, email us at contact@zedtozed.com, or post on zzUrbanSpaceman's blog on True Achievements. We'd love to hear from you! Also check out the Zed to Zed Podcast Leaderboard. Opening/closing music: "Jive Bot" by Jake Kaufman from the game Mighty Switch Force! developed and published by WayForward Technologies Break music: "Game Cool Dubstep Mode Logo" by Sparximer Gamerscore Boot Camp music: "Tally Screen" by Jake Kaufman from the game Mighty Switch Force! developed and published by WayForward Technologies Record Scratch sound by luffy I Am a Gummy Bear (The Gummy Bear Song) [Party Pop Remix] by Gummibär All audio production and podcast backend support provided by Tarragon Allen. Show notes by Tarragon Allen and Jo Carter. Hosts: Brandon Fream aka "Freamwhole" - TrueAchievements - Xbox Tarragon Allen aka "zzUrbanSpaceman" - TrueAchievements - Xbox Randy aka "Crandy" - TrueAchievements - Xbox Jo aka "angelsk" (in the Spoilercast and the show notes) - TrueAchievements - Xbox 0:00:00 - Intro Achievement Sponsor: Psychotic Prankster from Fallout 3 and Prankster's Return from Fallout 4 Ew - this sounds like a horrible achievement! (Jo) New segment by Crandy: Mug of the week: 36 USF Law Review 2001-2002 Crandy's tea: Southern Peach Tea by Stash Rey's Goop Recipe (this is now the official recipe) - super green! PSA: MASTERMAXX713 happy to help people with Famous Piñata from Viva Piñata: Trouble In Paradise Freamwhole's NCAA contest becomes the official True Achievements Ultimate Head to Head Contest (UHH!) NOTE: Rules have been clarified - now includes your whole Game Collection if you want Make sure you get your Game Collection in order before end of March 11 (registration open March 4) A little something special for all of you 0:11:06 - Listener Feedback Thanks for listening and sending in your feedback! yellow lego guy; Spazpol; Kez001; Beg Ell; Buckmarley155; Facial La Fleur; MclovinLegend; Jawelin; Mighty Mango; NBA Kirkland; Razzourus; Cky616craig1; NexusPlexus; Xtowers; Jo's Mum!; Weasel Pizza; Johnny Zarpentine @Jzarp43; Dan Taylor @GodOfCyanide; Craig Waddington @craigkilldya; Rich Stone aka TrueAchievement @richstone99; Frank Hardy @HardyFrank of the Cult of Frank What does happen after the tutorial in Avatar? Has anyone actually played the whole game? Reformatting of the gamerscore bootcamp - Twitter Poll The Potentially Endless Bean Dive has passed the 3 year mark! Wow.  MADeyePadEYE, Montana97 and seamonkeypowder are still going strong. People like Jo :) Jo is happy. We want the dream of being able to 100% even if we don't ever reach it.  However, is this a good reason not to start a game? There is no wrong way to play. We all have scars. But we hate price gouging content - and we don't want to support those games (e.g: Call of Duty and $15 map packs), especially if we're going for achievements; however, if you put 100s of hours into it, then it's worth it for you (Thanks Big El for the discussion point). Re: last week's video game movie discussion - I like the Mario movie (Jo), controversial, I know - but so bad it's good :) Sausage weekend….. okay….. Far Cry the Movie Screencheat (or screen peeking) - cool concept for a game (discussion re: Goldeneye, Oddjob was too small) My favourite movie tie-in video game is the LEGO Movie Videogame :) (Jo) - “Everything is awesome” - spaceship, Spaceship, SPACESHIP! Quantum Break has gone gold - play it on April 5th (hopefully) 0:50:57 - Recap Tarragon: ROBLOX (for the daily) Layers of Fear (4 pairs of pants scary) - BethBear guide on TA Bioshock 2 (KO) MP Zheroes (RARGH!) Randy: Bioshock 2 (KO) MP ROBLOX (for the daily) Killer Instinct Perfect Dark Zero (in Rare Replay) Flight Control in Airplane Mode Pool Pro Online 3 GRAW (DRINK!) Wolfenstein (360) Tarragon and Randy rant about how bad Windows Phone is. If you reset it, then you can't access anything you had saved on an SD card (bad!) #crandysrants #tarrysrants Brandon: Guacamelee Lovers in a Dangerous Spacetime (for the Achievement Scavenger Hunt this week) with his 7 year old son ROBLOX (20 days complete) Destiny (Titan Mastery) - completing Feb monthly goals Losing a streak is officially "Pulling a Fream" Abandoning monthly goals for the show However, Brandon is planning on finishing 2 Kinect Fun Labs (inc Avatar Kinect) and Wreckateer (DLC and Goblins), and AC: Revelations inc the Lost Archive #marchgoals 1:06:43 - News and Talking Zeds RedmptionDenied hit 990k GS, 1 million in mid to late March? Stallion83 to hit 1.3 million on 2 year anniversary of 1 million GS (March 13 2016) New Game and Achievement Notifications on True Achievements - Challenges (Xtowers was replaced by a robot), Knobs and Discos, and Server Closures. Division Beta - 6.4 million people participated Alan Wake's Return trademark filled by Remedy Jay and Silent Bob video game (on Fig) - may be ported to Xbox One Naughty Dog stole artwork from AC4: Black Flag for Uncharted trailer - they apologised and released a new trailer Vivendi trying to get back in the game industry: Vivendi's Fight for Gameloft Goes Hostile Vivendi Ubisoft takeover might happen Fallout 4 mode support coming in April for PC, and a month later for Xbox One. Question, what will be the mods effect on gamerscore? Will they be disabled? Does Bethesda care? 1:35:42 - Shovelware Cemetery What is Shovelware? Hero Defense - Haunted Island on Steam by Uber Strategist (publisher) and Happy Tuesday (developer) Verdict: Set it free or Bury it? Reasonable achievement list - waiting to hear if it'll come to Xbox. ROBLOX (half a star) Verdict: Set it free or Bury it Earn money from Roblox For reference, half star games: Bug Village (WP) Tony Hawk: RIDE Easy 1k 1:54:31 - Backwards Compatibility Geometry Wars: Retro Evolved Carcassonne DOOM (New) will come with DOOM 1 and DOOM 2 as a pre-order bonus GRAW (DRINK!) 1:55:47 - Knobs and Discos Halo 4 Challenge related achievements are (hopefully temporarily) discontinued - server is down for challenges - affects: The Challenged The Challenger Game delay: Assetto Corsa, pushed back to June 01:57:18 The Zombie News Corner Capcom - Re-releasing Resident Evil 6 to Xbox One in June, 5 in Summer and 4 in the Fall (20th Anniversary) Kickstarter: Walking Dead All Out War Miniatures Game (now over) Zombies!!! Boardgame (played by Brandon) 2:01:27 - Outro GRAW (DRINK!) I'm a Gummi Bear but not this kind 2:06:29 - Life Is Strange Spoilercast Life is Strange Walkthrough by our own Jo Carter   Glossary of Xbox Gamerscore and achievement jargon and terms: http://zedtozed.com/xbox-gamerscore-and-achievement-glossary

Rich Stone discusses science in Iran in the face of economic sanctions. David Grimm brings stories on sleep deprivation and the common cold, plastic in birds, and counting trees. Hosted by Sarah Crespi. [Image credit: Credit: Alessandro Marongiu / Demotix /Corbis]

Rich Stone discusses science in Iran in the face of economic sanctions. David Grimm brings stories on sleep deprivation and the common cold, plastic in birds, and counting trees. Hosted by Sarah Crespi. [Image credit: Credit: Alessandro Marongiu / Demotix /Corbis]

The first Sintillate Sessions features tracks from the new album 'Sintillate Marbella 2014’, available from iTunes on May 12, 2014. Sintillate’s musical director Rich Stone provides the guest mix. Hosted by Debbie Mac.Tracklisting: 1. SIGMA - Nobody To Love2. Tube and Berger ft. Juliet Sikora - Set It Off3. EDX - Cool You Off4. Disclosure ft. Sasha Keable - Voices5. Redlight ft. Lotti - 366. Jamiroquai - Space Cowboy (David Morales Remix)7. Josh Butler - Got A Feeling (Bontan and Pleasurekraft Remix)8. Shadowchild ft. Takura - Friday9. Ten Walls and Everything But The Girl - Missing Elephants (Stonez bootleg)10. Oliver $ & Jimi Jules - Pushing on11. Route 94, Jess Glynne - My Love12. Patrick Topping - Forget13. Kiesza - Hideaway14. Marlon Hoffstadt, Dansson - Shake that15. Second City - I wanna feel16. Sage the Gemini - Gas Pedal (Motez edit)17. Larse - So long (Nice7 remix)